求助西地那非原料藥信息   [更多]

急需冷敷凝膠、冷敷貼及傷口敷料的一類醫(yī)療器械全套備案申請(qǐng)資料   [更多]

文獻(xiàn)： 1、" Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. " Pharmacotherapy 2007;27:290–8. Page RL, Schwiesow J, Hilts A. 2、Mucormycosis treated with posaconazole: review of 96 case reports. Crit Rev Microbiol 2013;39:310–24. Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. 3、Tarantino MD, Fogarty P, Mayer B, Vasey SY, Brainsky A. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia. Blood Coagul Fibrinolysis. 2013 Apr;24(3):284-96. doi: 10.1097/MBC.0b013e32835fac99. 4、J Med Chem, 51: 4632～4640. Org. Process Res. Dev. 2019, 23, 9, 2057-2068 Pharmazie 73(9):494-497 · September 2018 5、中國醫(yī)藥工業(yè)雜志 2012， 43（8）， 644-646 6、精細(xì)化工中間體2013，43（2），46-48 7、精細(xì)化工中間體2011，41（4），46-48 8、中國現(xiàn)代應(yīng)用藥學(xué)2011，28（1），58-59 9、Chemical biology&Drug Design 2014, 83(3), 306-316 10、Letters in organic chemistry 2012, 9(4), 276-279 11、Medicines Evidence Commentary : Chronic kidney disease: calcium-based versus non-calcium-based phosphate binders Source: National Institute for Health and Care Excellence - NICE - 21 January 2014 - Publisher: National Institute for Health and Care Excellence (NICE) 12、double-blind comparison of calcium chloride and calcium gluconate therapies for hypocalcemia in critically ill children 13、J. Med. Chem. 2018, 61, 5304?5322. 14、Chem. Biol. Drug Des. 2014, 83, 306?316. 15、J. Pharm. Biomed. Anal. 2009, 50, 144?150. 16、Int. J. Pharm. Sci. 2016, 8, 97?102. 17、J. Pharm. Biomed. Anal. 2010, 52, 493?507. 18、Org. Process Res. Dev. 2013, 17, 1036?1041. 19、Beilstein J. Org. Chem. 2011, 7, 442? 495. 20、Bioorg. Med. Chem. Lett. 2014, 24, 1108?1110. 21、New Activated PEG Derivatives for Affinity Partitioning 22、Population incidence and mortality of sepsis in an urban African setting 2013-2016 23、Association of the Quick Sequential (Sepsis-Related) Organ Failure Assessment (qSOFA) Score With Excess Hospital Mortality in   [更多]

1、Arzneimittelforschung. 1985;35(7A):1203-8. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y. Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. 2、Arzneimittelforschung. 1985;35(7A):1149-54. K Kawamura, K Watanabe, Y Kimura. Effect of cilostazol, a new antithrombotic drug, on cerebral circulation 3、Gel formation of cefpodoxime proxetil 4、Gas chromatographic analysis of fosfomycin in plasma for pharmacokinetic analysis. GK Webster, RG Bell - Journal of AOAC International, 1999 - europepmc.org 5、Rydell N, Butler J, Balazs EA. Hyaluronic acid in synovial fluid.Ⅵ. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of the arthritis in track horses. Acta Vet Scand, 1970,11:139~146 6、Peyron JG, Balazs EA. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joints. Pathol Biol, 1974, 22:731~736 7、Weiss C, Balazs EA, St Onge R, et al. Clinical studies of the intra-articular injection of Healon in the treatment of osteoarthritis of human knee. Semin Arhtritis Rheum, 1980, 11(Suppl 1):143~144 8、Punzi L, Schiavon F, Ramonda R, et al. Intra-articular hyaluronic acid in the treatment of inflammatory and non-inflammatory knee diffusions. Curr Ther Res, 1988, 43:643~647 9、Nolan JP, reducing Catheter Related Bacteraemia in Haemodialysis. Vascular Access Soc. 5th Int. Congress of Vascular Access Soc, Nice, 2007 10、Arzneimittelforschung. 1984;34(9):948-52. Iron derivatives of modified milk protein.   [更多]

需求內(nèi)容在圖片里面   [更多]

1、Przemysl Chemiczny, 85(5), 349-350; 2006 2、Polymorphism of sodium valproate 【作 者】Mifsud, H.;Miguel, L.;Lavastre, V.;Maire, G. 【刊 名】Calorim. Anal. Therm. 【出版日期】1993 【卷 號(hào)】Vol.24 【頁 碼】309-312 3、Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC 4、[Standards, Options and Recommendations (SOR) for tumor markers in breast cancer. SOR Working Group] 5、Ital J Gastroenterol. 1995 Sep;27(7):376-7. TUDCA and UDCA are incorporated into hepatocyte membranes: different sites, but similar effects. Leuschner U1, Guldutuna S, Bhatti S, Elze A, Imhof M, You T, Zimmer G. Author information 6、AJHYA2 American Journal of Hygiene. (Baltimore, MD) V.1-80, 1921-64. For publisher information, see AJEPAS. Volume(issue)/page/year: 76,209,1962   [更多]

中藥新藥的藥學(xué)實(shí)驗(yàn)室設(shè)計(jì)圖紙，不包括藥理毒理、臨床，只做藥學(xué)資料用。（設(shè)備清單、SOP、人員建制也可一并提供）根據(jù)您提供的內(nèi)容詳細(xì)完整和詳細(xì)程度，可提高報(bào)酬。   [更多]

求購British Pharmacopoeia (Veterinary): Chlortetracycline Veterinary Oral Powder《BP2019》的藥典標(biāo)準(zhǔn)一份   [更多]

需求名稱：阿奇霉素顆粒（0.1g/袋）參比制劑備案的綜述資料 具體要求： 1.備案參比制劑為阿奇霉素干混懸劑原研地產(chǎn)化由輝瑞制藥有限公司生產(chǎn)，商品名：希舒美，規(guī)格：0.1g/包。 2.按照最新法規(guī)要求起草綜述資料 《參比制劑遴選申請(qǐng)資料》。 3.說明銷售數(shù)據(jù)來源。 4.查詢的數(shù)據(jù)最后有截屏或來源。 5.其他事項(xiàng)再溝通。 要求時(shí)間：請(qǐng)?jiān)?020年01月10日之前 交稿方式：直接點(diǎn)擊交稿在線交稿就是了，我會(huì)每天過來看的，謝謝各位藥智的戰(zhàn)友們   [更多]

1亞葉酸鈣原料BP2020版標(biāo)準(zhǔn)、EP10.0版 2左亞葉酸鈣原料BP2020版標(biāo)準(zhǔn)、EP10.0版 3左亞葉酸原料BP2020版標(biāo)準(zhǔn)、EP10.0版 4亞葉酸鈣注射液BP2020版標(biāo)準(zhǔn)、EP10.0版 5左亞葉酸鈣注射液BP2020版標(biāo)準(zhǔn)、EP10.0版 6左亞葉酸注射液BP2020版標(biāo)準(zhǔn)、EP10.0版   [更多]